Enanta Historical Financial Ratios
| ENTA Stock | USD 8.83 0.27 3.15% |
Enanta Pharmaceuticals is recently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.88 or Days Sales Outstanding of 65.25 will help investors to properly organize and evaluate Enanta Pharmaceuticals financial condition quickly.
Enanta |
About Enanta Financial Ratios Analysis
Enanta PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Enanta Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Enanta financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Enanta Pharmaceuticals history.
Enanta Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Enanta Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Enanta Pharmaceuticals sales, a figure that is much harder to manipulate than other Enanta Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Enanta Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Enanta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.At present, Enanta Pharmaceuticals' Price To Sales Ratio is projected to slightly decrease based on the last few years of reporting. The current year's PTB Ratio is expected to grow to 1.88, whereas Book Value Per Share is forecasted to decline to 5.91.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 45.54 | 38.52 | 27.41 | 26.04 | Receivables Turnover | 1.76 | 2.0 | 10.18 | 9.67 |
Enanta Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Enanta Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enanta Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 7.45 | 11.8 | 12.4 | 2.96 | 3.24 | 5.51 | |
| Ptb Ratio | 2.0 | 2.87 | 3.33 | 1.08 | 1.7 | 1.88 | |
| Days Sales Outstanding | 70.01 | 228.73 | 207.73 | 182.57 | 35.87 | 65.25 | |
| Book Value Per Share | 22.85 | 19.8 | 15.6 | 10.34 | 6.09 | 5.91 | |
| Free Cash Flow Yield | 0.006182 | (0.0617) | (0.0813) | (0.48) | (0.44) | (0.42) | |
| Operating Cash Flow Per Share | 0.36 | (3.47) | (4.12) | (4.92) | (3.72) | (3.54) | |
| Stock Based Compensation To Revenue | 0.16 | 0.22 | 0.31 | 0.36 | 0.4 | 0.42 | |
| Capex To Depreciation | 0.4 | 0.22 | 0.71 | 3.82 | 14.98 | 15.73 | |
| Pb Ratio | 2.0 | 2.87 | 3.33 | 1.08 | 1.7 | 1.88 | |
| Ev To Sales | 6.81 | 11.27 | 12.19 | 2.21 | 3.51 | 5.09 | |
| Free Cash Flow Per Share | 0.28 | (3.51) | (4.22) | (5.35) | (4.57) | (4.34) | |
| Roic | (0.0932) | (0.2) | (0.38) | (0.65) | (0.67) | (0.64) | |
| Net Income Per Share | (1.81) | (3.92) | (5.91) | (6.38) | (5.48) | (5.21) | |
| Sales General And Administrative To Revenue | 0.22 | 0.34 | 0.53 | 0.67 | 0.86 | 0.9 | |
| Research And Ddevelopement To Revenue | 1.12 | 1.79 | 1.91 | 2.06 | 1.94 | 2.04 | |
| Capex To Revenue | 0.0118 | 0.007726 | 0.0247 | 0.11 | 0.27 | 0.28 | |
| Cash Per Share | 14.95 | 17.12 | 19.39 | 12.1 | 17.64 | 16.41 | |
| Pocfratio | 128.79 | (16.37) | (12.61) | (2.27) | (2.78) | (2.64) | |
| Interest Coverage | 18.2 | 4.17 | (78.73) | (26.65) | 11.12 | 10.57 | |
| Capex To Operating Cash Flow | 0.2 | (0.0107) | (0.0251) | (0.0878) | (0.23) | (0.22) | |
| Pfcf Ratio | 161.77 | (16.2) | (12.3) | (2.09) | (2.27) | (2.15) | |
| Income Quality | (0.2) | 0.89 | 0.7 | 0.77 | 0.68 | 0.69 | |
| Roe | (0.0794) | (0.2) | (0.38) | (0.62) | (0.9) | (0.86) | |
| Ev To Operating Cash Flow | 117.64 | (15.63) | (12.38) | (1.7) | (3.01) | (2.86) | |
| Pe Ratio | (25.24) | (14.51) | (8.78) | (1.75) | (1.89) | (1.79) | |
| Return On Tangible Assets | 0.0947 | (0.0744) | (0.18) | (0.32) | (0.29) | (0.31) | |
| Ev To Free Cash Flow | 147.76 | (15.46) | (12.08) | (1.56) | (2.45) | (2.33) | |
| Earnings Yield | (0.0396) | (0.0689) | (0.11) | (0.57) | (0.53) | (0.5) | |
| Net Debt To E B I T D A | 2.08 | 0.5 | 0.16 | 0.48 | (0.15) | (0.16) | |
| Current Ratio | 18.08 | 8.82 | 10.45 | 6.73 | 5.21 | 4.95 | |
| Tangible Book Value Per Share | 22.85 | 19.9 | 15.85 | 10.34 | 6.09 | 5.93 | |
| Receivables Turnover | 5.21 | 1.6 | 1.76 | 2.0 | 10.18 | 9.67 | |
| Graham Number | 30.54 | 41.77 | 45.54 | 38.52 | 27.41 | 26.04 | |
| Shareholders Equity Per Share | 22.85 | 19.8 | 15.6 | 10.34 | 6.09 | 5.91 | |
| Capex Per Share | 0.0725 | 0.0372 | 0.1 | 0.43 | 0.85 | 0.89 | |
| Graham Net Net | 18.74 | 11.48 | 11.26 | 7.35 | 0.25 | 0.24 | |
| Revenue Per Share | 6.14 | 4.81 | 4.18 | 3.78 | 3.2 | 3.04 | |
| Interest Debt Per Share | 0.29 | 0.21 | 0.22 | 0.25 | 2.1 | 2.21 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (5.48) | Revenue Per Share 3.407 | Quarterly Revenue Growth (0.05) | Return On Assets (0.17) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.